Brilanestrant (GDC-0810) (XV, Fig. 3) is an estrogen receptor (ER) inhibitor for breast cancer that is selective and orally accessible, and created by Johnson Roche; very good in vitro activity has been seen in its preliminary research and development [29–31]. This evidence concerns the gene ESR1 and breast cancer.